Evan Charles Unger
Principal investigator.
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2016First federal award
$8.2MFederal grants as PI13 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
13 awards · $8.2M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 27, 2026 | NIH | SBIR Phase II Liquid Biopsy in Glioblastoma Treated with Chemoradiation and an Oxygen Therapeutic | $1.1M | — |
| Sep 23, 2025 | NIH | SBIR Phase II Liquid Biopsy in Glioblastoma Treated with Chemoradiation and an Oxygen Therapeutic | $919K | — |
| Sep 18, 2023 | NIH | SBIR Phase II Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma | $493K | — |
| Jun 28, 2022 | NIH | SBIR Phase II Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma | $1.0M | — |
| Sep 2, 2021 | NIH | STTR Phase I NanO2 as a Cerebroprotectant in a tMCAO Stroke Model in Mice | $478K | — |
| Jun 17, 2019 | NIH | SBIR Phase II Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development | $1.0M | — |
| Jul 12, 2018 | NIH | SBIR Phase II Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development | $964K | — |
| Dec 1, 2017 | NIH | SBIR Phase I Development of a syringe/sonication device employed to administer DDFPe in the prehospital setting | $144K | — |
| Sep 12, 2017 | NIH | SBIR Phase II Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma | $1.0M | — |
| Apr 1, 2017 | NIH | SBIR Phase I Dodecafluoropentane Prevents Ischemia Reperfusion Injury in Contemporary Acute Myocardial Infarction Management | $318K | — |
| Sep 19, 2016 | NIH | STTR Phase I B7-H3-Targeted Contrast Agent for Ultrasonic Imaging of Breast Cancer | $299K | — |
| Aug 25, 2016 | NIH | STTR Phase I Targeted and Non-targeted Microbubbles for Pediatric Applications | $243K | — |
| Mar 11, 2016 | NIH | STTR Phase I Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development | $298K | — |
Peer ranks
Federal funding#24
Awards as PI#30
Patents#27
Companies
No tracked company linked yet.
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.